文献速递肾小球疾病

血尿的全基因组关联研究

GWAS of Hematuria.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-04-26

研究利用英国生物银行白种英国人参与者的汇总统计识别与血尿相关的遗传变异,并通过排除泌尿生殖系统疾病富集肾小球性血尿。共纳入16,866例血尿病例和391,420例对照,鉴定出六个达到全基因组显著性的位点(PDPN、COL4A4-COL4A3、HLA-B、SORL1、PLLP和TGFB1),其中三个为新发现位点并在deCODE数据集中重复。

要点

  • 共纳入16,866例血尿病例和391,420例对照,病例尿白蛋白肌酐比更高且eGFR更低。
  • 六个位点达到全基因组显著性:PDPN、COL4A4-COL4A3、HLA-B、SORL1、PLLP和TGFB1。
  • 三个新位点(PDPN、SORL1、PLLP)在deCODE数据集试纸血尿中重复。

核心结论

  • 研究识别出六个与血尿相关的位点,包括COL4A4-COL4A3和HLA-B中的独立变异,并报告了三个新位点,其中PDPN的内含子变异在足细胞中表达。

研究设计与样本

  • 利用汇总统计在英国生物银行白种英国人参与者中识别与血尿相关的遗传变异,并通过排除泌尿生殖系统疾病富集肾小球性血尿。
  • 对2号染色体COL4A4-COL4A3区域使用Trans-Omics for Precision Medicine Program重新填补,并进行序贯区域条件分析。
  • 使用填补的HLA单倍型对6号染色体MHC区域进行条件分析以识别独立变异。

主要发现

  • 共纳入16,866例血尿病例和391,420例对照。
  • 病例较对照尿白蛋白肌酐比更高(女性:13.01 mg/g [8.05-21.33] 对 12.12 mg/g [7.61-19.29];P<0.001;男性:8.85 mg/g [5.66-16.19] 对 7.52 mg/g [5.04-12.39];P<0.001)。
  • 病例较对照eGFR更低(女性:88±14 对 90±13 ml/min per 1.72 m2;P<0.001;男性:87±15 对 90±13 ml/min per 1.72 m2;P<0.001)。
  • 六个位点(PDPN、COL4A4-COL4A3、HLA-B、SORL1、PLLP和TGFB1)达到全基因组显著性(P<5E-8)。
  • 2号染色体COL4A4 p.Ser969X(rs35138315;次要等位基因频率=0.00035;P<7.95E-35;比值比87.3;95%置信区间47.9至159.0)关联最显著;条件分析后COL4A3 p.Gly695Arg(rs200287952;次要等位基因频率=0.00021;P<2.16E-7;比值比45.5;95%置信区间11.8至168.0)和COL4A4内含子25常见变异(rs58261427;次要等位基因频率=0.214;P<2.00E-9;比值比1.09;95%置信区间1.06至1.12)仍与血尿相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Glomerular hematuria has varied causes but can have a genetic basis, including Alport syndrome and IgA nephropathy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used summary statistics to identify genetic variants associated with hematuria in White British UK Biobank participants. Individuals with glomerular hematuria were enriched by excluding participants with genitourinary conditions. A strongly associated locus on chromosome 2 (COL4A4-COL4A3) was identified. The region was reimputed using the Trans-Omics for Precision Medicine Program followed by sequential rounds of regional conditional analysis, conditioning on previous genetic signals. Similarly, we applied conditional analysis to identify independent variants in the MHC region on chromosome 6 using imputed HLA haplotypes. RESULTS: In total, 16,866 hematuria cases and 391,420 controls were included. Cases had higher urinary albumin-creatinine compared with controls (women: 13.01 mg/g [8.05-21.33] versus 12.12 mg/g [7.61-19.29]; P<0.001; men: 8.85 mg/g [5.66-16.19] versus 7.52 mg/g [5.04-12.39]; P<0.001) and lower eGFR (women: 88±14 versus 90±13 ml/min per 1.72 m2; P<0.001; men: 87±15 versus 90±13 ml/min per 1.72 m2; P<0.001), supporting enrichment of glomerular hematuria. Variants at six loci (PDPN, COL4A4-COL4A3, HLA-B, SORL1, PLLP, and TGFB1) met genome-wide significance (P<5E-8). At chromosome 2, COL4A4 p.Ser969X (rs35138315; minor allele frequency=0.00035; P<7.95E-35; odds ratio, 87.3; 95% confidence interval, 47.9 to 159.0) had the most significant association, and two variants in the locus remained associated with hematuria after conditioning for this variant: COL4A3 p.Gly695Arg (rs200287952; minor allele frequency=0.00021; P<2.16E-7; odds ratio, 45.5; 95% confidence interval, 11.8 to 168.0) and a common COL4A4 intron 25 variant (not previously reported; rs58261427; minor allele frequency=0.214; P<2.00E-9; odds ratio, 1.09; 95% confidence interval, 1.06 to 1.12). Of the HLA haplotypes, HLA-B (*0801; minor allele frequency=0.14; P<4.41E-24; odds ratio, 0.84; 95% confidence interval, 0.82 to 0.88) displayed the most statistically significant association. For remaining loci, we identified three novel associations, which were replicated in the deCODE dataset for dipstick hematuria (nearest genes: PDPN, SORL1, and PLLP). CONCLUSIONS: Our study identifies six loci associated with hematuria, including independent variants in COL4A4-COL4A3 and HLA-B. Additionally, three novel loci are reported, including an association with an intronic variant in PDPN expressed in the podocyte. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2022_04_26_CJN13711021.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Gagliano Taliun SA, Sulem P, Sveinbjornsson G, et al. GWAS of Hematuria. Clin J Am Soc Nephrol. 2022. PMID: 35474271. doi:10.2215/CJN.13711021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。